Hudson Bay Capital Management
CYTK icon

Hudson Bay Capital Management’s Cytokinetics CYTK Stock Holding History

Hudson Bay Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6M Buy
+161,000
New +$10.2M 0.04% 303

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hudson Bay Capital Management's CYTK Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Cytokinetics (CYTK) stake by 77% in Q1 2026, selling an estimated $8.64M and leaving 39,470 shares worth $2.6M. The position accounts for 0.01% of the portfolio, ranked #694.

Hudson Bay Capital Management first reported a position in CYTK in Q4 2019 and has held it in 14 quarters since. The position peaked at $17.4M in Q1 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Hudson Bay Capital Management held 39,470 shares of Cytokinetics worth $2.6M as of Q1 2026.
  • Hudson Bay Capital Management sold 135,880 Cytokinetics shares in Q1 2026, an estimated $8.64M.
  • Cytokinetics made up 0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #694 holding.
  • Hudson Bay Capital Management first reported a position in Cytokinetics in Q4 2019 and has held it in 14 quarters since.
  • Hudson Bay Capital Management's Cytokinetics position peaked at $17.4M in Q1 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.